3 Things You Can Count On With Illumina's Q4 Earnings Results

Last year proved to be a disappointment for Illumina (NASDAQ: ILMN) investors. Although the genomic-sequencing pioneer's shares rose by nearly 11%, it badly underperformed the S&P 500 index. Illumina started off 2020 with bad news as well by throwing in the towel on its planned acquisition of Pacific Biosciences of California because of regulatory obstacles.